Metabolic therapy for the diabetic patients with ischaemic heart disease

Coronary Artery Disease

Volumn 16, Issue SUPPL. 1, 2005, Pages

  Rosano, Giuseppe M C ^a   Vitale, Cristiana ^a   Volterrani, Maurizio ^a   Fini, Massimo ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Angina; Coronary artery disease; Diabetes; Disease; Heart; Metabolism; Prognosis

Indexed keywords

FATTY ACID; TRIMETAZIDINE; VASODILATOR AGENT;

ATHEROGENESIS; DIABETES MELLITUS; ENERGY METABOLISM; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; HEART MUSCLE METABOLISM; HEART PERFUSION; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC BALANCE; PRIORITY JOURNAL; REVIEW; VASCULARIZATION; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; HEART MUSCLE; HEART MUSCLE ISCHEMIA; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

CARBOHYDRATE METABOLISM; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 33646440509     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200511001-00004     Document Type: Review

References (43)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-1431.
2. Kanters SD, Banga JD, Stolk RP, Algra A. Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. Vasc Med 1999; 4:67-75.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
4. Langer A, Freeman MR, Josse RG, Steiner G, Armstrong PW. Detection of silent myocardial ischaemia in diabetes mellitus. Am J Cardiol 1991; 67:1073-1078.
5. Zarich S, Waxman S, Freeman RT, Mittleman M, Hegarty P, Nesto RW. Effect of autonomic nervous system on the circadian pattern of myocardial ischaemia in diabetes mellitus. J Am Coll Cardiol 1994; 24:956-962.
6. Ahmed SS, Jaferi GA, Narang RM, Regan TJ. Preclinical abnormality of left ventricular function in diabetes mellitus. Am Heart J 1975; 89:153-158.
7. Sykes CA, Wright AD, Malins JM, Pentecost BL. Changes in systolic time intervals during treatment of diabetes mellitus. Br Heart J 1977; 39:255-259.
8. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, Haider B. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977; 60:884-899.
9. Zoneraich S, Silverman G, Zoneraich O. Primary myocardial disease, diabetes mellitus, and small vessel disease. Am Heart J 1980; 100:754-755.
10. Farah AE, Alousi AA. The actions of insulin on cardiac contractility. Life Sci 1981; 29:975-1000.
11. Parsonage W, Hetmanski D, Cowley A. Differentiation of the metabolic and vascular effects of insulin in insulin resistance in patients with chronic heart failure. Am J Cardiol 2002; 89:696-703.
12. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997; 34:25-33.
13. Stanley WC, Hall JL, Smith KR, Cartee GD, Hacker TA, Wisneski JA. Myocardial glucose transporters and glycolytic metabolism during ischaemia in hyperglycemic diabetic swine. Metabolism 1994; 43:61-69.
14. Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 1998; 180:53-57.
15. Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 2002; 106:606-612.
16. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997; 34:25-33.
17. Hall JL, Lopaschuk GD, Barr A, Bringas J, Pizzurro RD, Stanley WC. Increased cardiac fatty acid uptake with dobutamine infusion in swine is accompanied by a decrease in malonyl CoA levels. Cardiovasc Res 1996; 32:879-885.
18. Nicholl TA, Lopaschuk GD, McNeill JH. Effects of free fatty acids and dichloroacetate on isolated working diabetic rat heart. Am J Physiol 1991; 261(4 Pt 2):H1053-H1059.
19. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-419.
20. Malmberg K, Ryden L, Hamsten A, Herlitz J, Walderstrom A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI study group. Eur Heart J 1996; 17:1337-1344.
21. Diaz R, Paolasso EC, Piegas LS, Tajer CD, Moreno MG, Corvalan R, et al. Metabolic modulation of acute myocardial infarction. The ECLA glucose- insulin-potassium pilot trial. Circulation 1998; 98:2227-2234.
22. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium (GIK) therapy for treatment of acute myocardial infarction: an overview of randomized placebo controlled trials. Circulation 1997; 96:1152-1156.
23. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86:580-588.
24. Lopaschuk GD. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis 2001; 12(Suppl 1):S8-S11.
25. Fabiani JN, Ponzio O, Emerit I, Massonet-Castel S, Paris M, Chevalier P, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg 1992; 33:486-491.
26. Kober G, Buck T, Sievert H, Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J 1992; 13:1109-1115.
27. Steg PG, Grollier G, Gallay P, Morice M, Karrillon GJ, Benamer H, et al. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 2001; 77:263-273.
28. Dalla Volta S, Maraglino G, Della Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double-blind crossover study. Cardiovasc Drugs Ther 1990; 4:853-859.
29. Detry JM, Sellier P, PennaLorte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994; 37:279-288.
30. Michaelides AP. Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest 1997; 13:8-14.
31. Manchanda SC. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997; 78: 353-357.
32. Szwed H, Pachocki R, Domnzal-Bochenska M, Szymczak K, Szydlowski Z, Paradowski A, et al. The antiischaemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-I. Cardiovasc Drugs Ther 1999; 13:215-220.
33. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003; 2:16.
34. Rebrova TIu, Afanas'eva SA, Perchatkin VA, Maksimov IV, Markov VA. The protective effect of trimetazidine on the myocardium against reperfusion injury during thrombolytic therapy of acute infarction. Eksp Klin Farmakol 2004; 67:27-30.
35. Barsotti A, Di Napoli P. Trimetazidine and cardioprotection during ischaemia-reperfusion. Ital Heart J 2004; 5(Suppl 2):29S-36S.
36. Ikizler M, Dernek S, Sevin B, Kural T. Trimetazidine improves recovery during reperfusion in isolated rat hearts after prolonged ischaemia. Anadolu Kardiyol Derg 2003; 3:303-308.
37. Belardinelli R. ischaemic heart disease and left ventricular dysfunction: the role of trimetazidine [in Italian]. Ital Heart J 2004; 5(Suppl 2):23S-28S.
38. Feola M, Biggi A, Francini A, Leonardi G, Ribichini F, Ferrero V, Uslenghi E. Trimetazidine improves myocardial perfusion and left ventricular function in ischaemic left ventricular dysfunction. Clin Nucl Med 2004; 29:117-118.
39. Fragasso G, Piatti PM, Monti L, Palloshi A, Lu C, Valsecchi G, et al. Acute effects of heparin administration on the ischaemic threshold of patients with coronary artery disease: evaluation of the protective role of the metabolic modulator trimetazidine. J Am Coll Cardiol 2002; 39:413-419.
40. Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischaemic cardiomyopathy. Am Heart J 2003; 146:E18.
41. Monti LD, Setola E, Fragasso G, Camisasca RP, Lucotti P, Galluccio E, et al. Metabolic and endothelial effects of trimetazidine on forearm muscle in patients with type 2 diabetes and ischaemic cardiomyopathy. Am J Physiol Endocrinol Metab (in press; published online September 20, 2005).
42. Sellier P, Broustet JP. Assessment of anti-ischaemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs 2003; 3:361-369.
43. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25:1814-1821.